Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

Judge Wants More 'Bellwether' Trials In Litigation Over Merck's Fosamax

The federal judge overseeing hundreds of lawsuits involving Merck & Co.'s osteoporosis drug Fosamax wants to hear two additional "bellwether" cases beyond the two scheduled for later this year.

Merck is facing more than 900 cases in state and federal court generally alleging that the use of Fosamax can cause a jaw-destroying condition known as osteonecrosis and that Merck failed to properly warn of this risk. The cases are being heard individually.

Read the full Wall Street Journal story, "Judge Wants More 'Bellwether' Trials in Litigation Over Merck's Fosamax"

Join the Conversation

Advertisement. Closing in 15 seconds.